While the FDA waits for someone to come up with a plan to improve the accelerated approval program, some argue that as it is, drugs are not getting to the people who need them.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Tysabri raises alarm bells on drug class
Iressa failure raises fears about accelerated approvals
Web links
Rights and permissions
About this article
Cite this article
Fox, J. Conflicting signals on US accelerated approvals. Nat Biotechnol 23, 1027–1028 (2005). https://doi.org/10.1038/nbt0905-1027
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0905-1027
